Remarkably , at peak immunogenicity , the concentration of anti-V1V2 IgG , a response associated with a reduced risk of HIV-1 acquisition in the RV144 adult vaccine trial , was 22-fold higher in Chiron vaccine recipients , compared with RV144 vaccinees .